Market Research Logo


FirstWord belongs to a business group that forms one of the world's largest healthcare knowledge networks. Drawing from these knowledge assets, FirstWord reports deliver insight, analysis and the latest thinking on important trends and the most challenging issues affecting the pharmaceutical industry today. Highly-focused, relevant, up-to-date, actionable intelligence - reports that deliver vital intelligence to give a competitive edge.
...Show More ...Show Less

483 Reports from FirstWord

  • CLL [2016]: Bulletin #3

    ... the Phase III results published from the GENUINE study investigating TG Therapeutics’ novel anti-CD20 monoclonal antibody (mAb) in combination with J&J/AbbVie’s Imbruvica (ibrutinib). Topics covered include KOL opinions on the approval of Celltrion/Mundipharma biosimilar rituximab ... Read More

  • NSCLC [2016]: Bulletin #3

    ... treatment of BRAF V600-positive advanced NSCLC; Takeda's Alunbrig (brigatinib) being granted accelerated approval in the US for the treatment of patients with metastatic ALK-positive NSCLC who have progressed on or are intolerant to Xalkori (crizotinib; ... Read More

  • The Future of Biosimilars in Europe: Mapping critical uncertainties and the impact of future events

    ... are on biosimilar oncology monoclonal antibodies (mAbs). Experts say they’re the next frontier in the European biosimilars market, but warn that they may not achieve widespread uptake unless stakeholders can put doctors’ and patients’ biggest ... Read More

  • Market Access Impact (EU5) [Growth Hormone Deficiency]

    ... countries. Most brands lose market share because of them, but for some brands, perception may be an even bigger problem. As many as 16% of the doctors we surveyed either wouldn’t prescribe these brands, or ... Read More

  • NPS+ (EU5) [Melanoma]

    ... Can either one pull ahead? It won’t be easy. According to our survey, doctors recommend these brands for largely the same reasons, and may even see them as interchangeable. Find out how doctors rated your ... Read More

  • Medical Affairs Reputations (EU5) [MS]

    ... to the doctors on the receiving end? According to this latest survey, satisfaction levels are adequate but almost a quarter of physicians suggest that medical affairs teams could improve their attitude and practice. Is ‘satisfactory’ ... Read More

  • Market Access Impact (US) [Growth Hormone Deficiency]

    ... and most brands lose market share because of them. According to the endocrinologists we surveyed, that’s a problem with no single solution; many of them experience as many as 3 different barriers with any given ... Read More

  • NPS+ (US) [Melanoma]

    ... US-based medical oncologists and dermato-oncologists are optimistic about these two drugs, but haven’t had many opportunities to prescribe them. Meanwhile, the top 2 brands are comfortably ahead thanks mainly to widespread perceptions about their clinical ... Read More

  • NASH: KOL Insight [2017]

    ... next five years? Allergan/Tobira’s cenicriviroc and Gilead’s selonsertib have entered the Phase III pipeline but how do they compare with other agents, Intercept’s obeticholic acid and Genfit’s elafibranor. How important are improvements in fibrosis and ... Read More

  • Medical Affairs in Orphan Drugs

    ... the physician and patient populations are so much smaller – and the value of individual relationships is consequently higher as a result. But some players are achieving success with high-performing medical affairs teams and sophisticated ... Read More

  • Market Access Impact (US) [CLL]

    ... drug is clearly popular and others are playing ‘catch-up’ on the market share stakes – but what difference would it make if the landscape shifted and non-clinical constraints such as cost, availability, administrative restrictions, institutional ... Read More

  • Market Access Impact (US) [RCC]

    ... are preventing oncologists we surveyed from prescribing some brands. Are they costing your brand market share, or are you winning share from more expensive competitors? Which other barriers are keeping doctors from prescribing your brand? ... Read More

  • Market Access Impact (EU5) [RCC]

    ... EU5. The brands that can find a way to eliminate them stand to make important share gains. Especially in the middle of the market, where competition is lively, and at the bottom of the market, ... Read More

  • COPD [2017]

    ... Obstructive Lung Disease (GOLD) recommend LABA/LAMAs as first line therapy in symptomatic patients regardless of exacerbation risk, and KOLs agree. LABA/LAMA marketing companies set to benefit include AstraZeneca, Boehringer Ingelheim, GSK and Novartis, but which ... Read More

  • Psoriasis [2016]: Bulletin #3

    ... pivotal Phase III studies reporting the efficacy and safety of guselkumab (anti-IL23 monoclonal antibody [mAb]) in the treatment of adults with moderate to severe plaque psoriasis; Sun Pharmaceutical announcing new data from two pivotal Phase ... Read More

  • Payer Insights: MS [2016]: Bulletin #3

    ... the impact of the launch delay of generic Copaxone 40mg/ml and potential steps that Teva could take to retain market share of its branded Copaxone; approaches to reimbursing Alkermes’ ALKS 8700 and opinions on ways ... Read More

  • Real World Data -- Meeting payer needs

    ... Payers with stretched budgets are still struggling to make the case for ‘big ticket’ drugs. Whereas pharma is keen to prove that higher cost drugs are justified and will ultimately save money. But are payers ... Read More

  • Medical Affairs Reputations (EU5) [HIV]

    ... doing a better job. They identified specific medical affairs services where teams are not up to par, and recommended several ways teams can improve both the information they provide, and the way they provide it. ... Read More

  • How Payers Want to Work With Pharma

    ... approach to payer negotiations getting your message across? Too often pharma fails to provide the data and contracting innovation that will unlock the door to a deal. It can be better. Report Overview In How ... Read More

  • Medical Affairs Reputations (US) [HIV]

    ... job. In the past 6 months, only one of those teams reached out to more than 70% of the infectious disease specialists we surveyed. Survey respondents also had a lot to say about how teams ... Read More

  • NPS+ (EU5) [Asthma/COPD]

    ... of choice impacting brand loyalty? What do physicians really think about the leading brands? And are they talking positively or negatively about each to their peers? Brand marketers can find out everything they need to ... Read More

  • Ovarian Cancer [2017]

    ... Co.’s Zejula. How will AstraZeneca’s Lynparza fare in the rapidly growing PARP inhibitor market and will the newer therapies in this class prove their worth? Furthermore, a multitude of novel combinations are being evaluated in ... Read More

  • NPS+ (US) [Asthma/COPD]

    ... abundance of choice impacting brand loyalty? What do physicians think today about the leading brands? And are they talking positively or negatively about each to their peers? Brand marketers can find out everything they need ... Read More

  • Targeted Therapies in Asthma: KOL Insight: Update Bulletin [April 2017]

    ... of new data at the American Academy of Allergy, Asthma & Immunology Annual Meeting (AAAAI 2017) which demonstrates that efficacy of mepolizumab (Nucala) is not affected by the presence of nasal polyps (which can be ... Read More

  • Medical Affairs Reputations (US) [RCC]

    ... our survey of 100 medical oncologists. As part of list of suggested improvements, they identified at least 4 ways that teams for major renal cell carcinoma (RCC) treatments could do a better job of providing ... Read More

5 6 7 8 10 12 13 14

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook